Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eflornithine/sulindac - Panbela Therapeutics

Next Previous
Drug Profile

Eflornithine/sulindac - Panbela Therapeutics

Alternative Names: CPP-1X/sul; CPP-1X/sulindac; CPP1-x/sulindac; Flynpovi; Sulindac/CPP-1X; Sulindac/eflornithine - Panbela Therapeutics; TP 09

Latest Information Update: 08 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Arizona; University of California at Irvine
  • Developer Cancer Prevention Pharmaceuticals; National Cancer Institute (USA); Panbela Therapeutics
  • Class Antineoplastics; Basic amino acids; Diamino amino acids; Indenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Ornithine decarboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Familial adenomatous polyposis
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Familial adenomatous polyposis
  • Phase III Colorectal cancer
  • No development reported Pancreatic cancer

Most Recent Events

  • 05 Sep 2023 Panbela Therapeutics receives patent protection for production process of eflornithine/sulindac in Chile
  • 05 Sep 2023 Panbela Therapeutics has patent pending for eflornithine/sulindac in multiple countries
  • 04 Sep 2023 Panbela Therapeutics has patent protection for eflornithine/sulindac in USA, Australia, Mexico and Taiwan before September 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top